Literature DB >> 26273510

Osteoporosis Treatment: When to Discontinue and When to Re-start.

Silvano Adami1, Luca Idolazzi1, Elena Fracassi1, Davide Gatti1, Maurizio Rossini1.   

Abstract

A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike hormone replacement, denosumab or teriparatide, is associated with benefits extended even after treatment discontinuation. The extended benefits are most apparent for alendronate (ALN) and zoledronate (ZOL). A drug holiday might be considered in patients at low-moderate risk and who have been fully compliant with treatment, and who have had a response to treatment. In patients at low-moderate risk of fractures the decision to consider a drug holiday should be balanced also with the safety profile of each treatment.

Entities:  

Keywords:  bisphosphonates; duration of osteoporosis treatment; osteoporosis treatment

Year:  2013        PMID: 26273510      PMCID: PMC4472120          DOI: 10.4248/BR201304003

Source DB:  PubMed          Journal:  Bone Res        ISSN: 2095-4700            Impact factor:   13.567


  42 in total

1.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

2.  Safety of osteoanabolic therapy: a decade of experience.

Authors:  Cristiana Cipriani; Cristiana Capriani; Dinaz Irani; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

3.  Effect of stopping risedronate after long-term treatment on bone turnover.

Authors:  Richard Eastell; Rosemary A Hannon; Dietrich Wenderoth; Jesus Rodriguez-Moreno; Andrzej Sawicki
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

4.  The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.

Authors:  Davide Gatti; Ombretta Viapiana; Luca Idolazzi; Elena Fracassi; Maurizio Rossini; Silvano Adami
Journal:  J Clin Endocrinol Metab       Date:  2011-03-02       Impact factor: 5.958

Review 5.  Adverse effects of bisphosphonates.

Authors:  Bo Abrahamsen
Journal:  Calcif Tissue Int       Date:  2010-04-21       Impact factor: 4.333

6.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

9.  Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Authors:  Robert Lindsay; Wim H Scheele; Robert Neer; Gerhardt Pohl; Silvano Adami; Carlos Mautalen; Jean-Yves Reginster; Jan J Stepan; Stephen L Myers; Bruce H Mitlak
Journal:  Arch Intern Med       Date:  2004-10-11

Review 10.  Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Authors:  René Rizzoli; Jean-Yves Reginster; Steven Boonen; Gérard Bréart; Adolfo Diez-Perez; Dieter Felsenberg; Jean-Marc Kaufman; John A Kanis; Cyrus Cooper
Journal:  Calcif Tissue Int       Date:  2011-06-03       Impact factor: 4.333

View more
  1 in total

1.  GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.

Authors:  P Hadji; I Kyvernitakis; P H Kann; C Niedhart; L C Hofbauer; H Schwarz; A A Kurth; F Thomasius; M Schulte; M Intorcia; E Psachoulia; T Schmid
Journal:  Osteoporos Int       Date:  2016-05-12       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.